November 28, 2014 1:35 PM ET

Pharmaceuticals

Company Overview of Pernix Sleep, Inc.

Company Overview

Pernix Sleep, Inc., a specialty pharmaceutical company, engages in developing and commercializing prescription therapeutics to treat medical conditions. The company focuses on in-licensing, developing, and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Its products include Silenor, a nonscheduled prescription medication for the treatment of sleep maintenance insomnia, which include adults and the elderly who have sleep maintenance insomniaA type of insomnia, people with chronic sleep maintenance insomnia (insomnia lasting more than three weeks), and people with transient insomnia. Th...

10935 Vista Sorrento Parkway

Suite 250

San Diego, CA 92130

United States

Founded in 2003

36 Employees

Phone:

858-876-6500

Fax:

858-509-1761

Key Executives for Pernix Sleep, Inc.

Chief Executive Officer
Age: 50
Co-Founder
Age: 65
Chief Financial Officer
Age: 40
Senior Vice President
Age: 43
Senior Vice President of Technical Operations
Age: 45
Compensation as of Fiscal Year 2014.

Pernix Sleep, Inc. Key Developments

Pernix Sleep, Inc., Annual General Meeting, Jun 19, 2013

Pernix Sleep, Inc., Annual General Meeting, Jun 19, 2013., at 11:00 US Eastern Standard Time. Location: Pernix Therapeutics Holdings, Inc.. Agenda: To elect five directors for a term of one year; to approve, on an advisory basis, the company's executive compensation; to indicate, on an advisory basis, how frequently the company should hold an advisory vote on executive compensation; to ratify the selection of Cherry Bekaert LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2013; and to transact such other business as may properly come before the meeting or any postponement or adjournment thereof.

Somaxon Pharmaceuticals, Inc. Amends and Restates in its Certificate of Incorporation

Somaxon Pharmaceuticals, Inc. was amended and restated in its entirety to be substantially identical to the certificate of incorporation of merger sub as in effect immediately prior to the effective time of acquisition, except that the name of Somaxon became Pernix Sleep, Inc. Additionally, pursuant to the merger agreement, at the effective time, the bylaws of merger sub became the bylaws of Somaxon, except that the bylaws were amended to replace all references to Pernix Acquisition Corp. I with references to Pernix Sleep, Inc.

Somaxon Pharmaceuticals, Inc.(NasdaqCM:SOMX) dropped from NASDAQ Composite Index

Somaxon Pharmaceuticals, Inc. will be removed from NASDAQ Composite Index .

Similar Private Companies By Industry

Company Name Region
E. R. Squibb & Sons Inter-American Corporation United States
MicroSource Discovery Systems, Inc. United States
Plexxikon Inc. United States
Chelated Minerals Corporation United States
NeuroTherapeutics Pharma, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Pernix Sleep, Inc., please visit www.somaxon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.